zurück

Setmelanotide (obesity and the control of hunger associated with deficiency in POMC, PCSK1 or LEPR, adults and children ≥ 6 years of age)


Subject:

  • Active Substance: Setmelanotide
  • Name: Imcivree®
  • Therapeutic area: Obesity and the control of hunger
  • Pharmaceutical company: Rhythm Pharmaceuticals Inc.
     

Time table:

  • Start: 01.06.2022
  • Final decision by G-BA: 01.12.2022


Final decision:

  • Hint for a non-quantifiable additional benefit